Safety and Effectiveness of SA58 Nasal Spray Against COVID-19 Infection in Medical Personnel:An Open-Label,Blank-Controlled Study—Hohhot City,Inner Mongolia Autonomous Region,China,2022  

作　　者：Shujie Si Canrui Jin Jianping Li Yunlong Cao Biao Kan Feng Xue Xiaoliang Sunney Xie Liang Fang Gang Zeng Shuo Zhang Yaling Hu Xiaoping Dong 

机构地区：[1]Pharmacy Department,Inner Mongolia Fourth Hospital,Hohhot City,Inner Mongolia Autonomous Region,China [2]Clinical Research and Development Department,Sinovac Biotech Co.,Ltd.,Beijing,China [3]Biomedical Pioneering Innovation Center(BIOPIC),Peking University,Beijing,China [4]Changping Laboratory,Beijing,China [5]State Key Laboratory for Infectious Disease Prevention and Control,NHC Key Laboratory of Medical Virology and Viral Diseases,National Institute for Viral Disease Control and Prevention,Chinese Center for Disease Control and Prevention,Beijing,China [6]Research and Development Department,Sinovac Life Sciences Co.,Ltd.,Beijing,China [7]Inner Mongolia Blood Center,Hohhot City,Inner Mongolia Autonomous Region,China [8]Center for Biosafety Mega-Science,Chinese Academy of Sciences,Wuhan City,Hubei Province,China [9]China Academy of Chinese Medical Sciences,Beijing,China [10]Shanghai Institute of Infectious Diseases and Biosafety,Shanghai,China

出　　处：《China CDC weekly》2023年第10期218-222,共5页中国疾病预防控制中心周报（英文）

摘　　要：Summary What is already known about this topic?The active ingredient of the SA58 Nasal Spray is a broad-spectrum neutralizing antibody with a high neutralizing capacity against different Omicron subvariants in vitro studies.What is added by this report?This study demonstrated the safety and effectiveness of SA58 Nasal Spray against coronavirus disease 2019(COVID-19)infection in medical personnel for the first time.What are the implications for public health practice?This study provides an effective approach for the public to reduce their risk of COVID-19 infection.The findings of this research have the potential to significantly reduce the risk of infection and limit human-to-human transmission in the event of a COVID-19 outbreak.

关 键 词：neutral COV NASAL 

分 类 号：R563.1[医药卫生—呼吸系统]